Wednesday, January 10, 2024

NIVIDIA's Secret Biotech Partner

In April 2021, NVIDIA partnered with a tiny biotech to help power its AI-drug discovery platform.
In April 2021, NVIDIA partnered with a tiny biotech to help power its AI-drug discovery platform.͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  ͏‌  

Dear Fellow Investor,

In April 2021, NVIDIA partnered with a tiny biotech to help power its AI-drug discovery platform.

Six months later, its AI discovered a new treatment for multiple myeloma.

Six months after that, Eli Lilly signed a $425 million deal to have them develop new drugs.

Six months after that, Bristol Myers Squibb signed a $2.7 billion deal to have its AI-platform develop new drugs.

That's why Bill Gates, BlackRock and Morgan Stanley own 16 million shares of this "little-known" company.

Get the name of this small-cap here >>>

"The Buck Stops Here,"

DISCLAIMER: This communication includes advertising material and PAID ADVERTISEMENTS provided to our customers. Stocks and options trading have large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the stocks and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell stocks or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed in this report. The past performance of any trading system or methodology is not necessarily indicative of future results. All trades, patterns, charts, systems, etc., discussed in this report are for illustrative purposes only and not to be construed as specific advisory recommendations. Information contained in this correspondence is intended for informational purposes only and was obtained from sources believed to be reliable. Information is in no way guaranteed. No guarantee of any kind is implied or possible where projections of future conditions are attempted.


This email was sent to edwardlorilla1986.paxforex@blogger.com. Don't want to receive these emails anymore? Unsubscribe
Prince Report (Meza Media LLC), 1001 Fischer Blvd Suite 3, #114 Toms River, NJ 08753

No comments:

Post a Comment

Welcome to Bernie Schaeffer's Award-Winning Option Advisor

Congratulations! By signing up for Option Advisor, you just took the first step towards becoming a successful trader and pot...